These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33689217)

  • 21. Heart failure in Finland: clinical characteristics, mortality, and healthcare resource use.
    Huusko J; Kurki S; Toppila I; Purmonen T; Lassenius M; Gullberg E; Wirta SB; Ukkonen H
    ESC Heart Fail; 2019 Aug; 6(4):603-612. PubMed ID: 31054212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study.
    Kurgansky KE; Schubert P; Parker R; Djousse L; Riebman JB; Gagnon DR; Joseph J
    BMC Cardiovasc Disord; 2020 Feb; 20(1):92. PubMed ID: 32101141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
    Zacà V
    J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):597-605. PubMed ID: 30160656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters.
    Montembeau SC; Rao BR; Mitchell AR; Speight CD; Allen LA; Halpern SD; Ko YA; Matlock DD; Moore MA; Morris AA; Scherer LD; Ubel P; Dickert NW
    Am Heart J; 2024 Mar; 269():84-93. PubMed ID: 38096946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial.
    Hashemi D; Dettmann L; Trippel TD; Holzendorf V; Petutschnigg J; Wachter R; Hasenfuß G; Pieske B; Zapf A; Edelmann F
    ESC Heart Fail; 2020 Jun; 7(3):786-793. PubMed ID: 31984661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature.
    Wierda E; Dickhoff C; Handoko ML; Oosterom L; Kok WE; de Rover Y; de Mol BAJM; van Heerebeek L; Schroeder-Tanka JM
    ESC Heart Fail; 2020 Jun; 7(3):892-902. PubMed ID: 32159279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
    J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry.
    Kang J; Park JJ; Cho YJ; Oh IY; Park HA; Lee SE; Kim MS; Cho HJ; Lee HY; Choi JO; Hwang KK; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29535141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare Costs for Acute Hospitalized and Chronic Heart Failure in South Korea: A Multi-Center Retrospective Cohort Study.
    Ku H; Chung WJ; Lee HY; Yoo BS; Choi JO; Han SW; Jang J; Lee EK; Kang SM
    Yonsei Med J; 2017 Sep; 58(5):944-953. PubMed ID: 28792137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States.
    Greene SJ; Triana TS; Ionescu-Ittu R; Burne RM; Guérin A; Borentain M; Kessler PD; Tugcu A; DeSouza MM; Felker GM; Chen L
    JACC Heart Fail; 2020 Nov; 8(11):943-953. PubMed ID: 32800512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial.
    Jiménez-Marrero S; Yun S; Cainzos-Achirica M; Enjuanes C; Garay A; Farre N; Verdú JM; Linas A; Ruiz P; Hidalgo E; Calero E; Comín-Colet J
    J Telemed Telecare; 2020; 26(1-2):64-72. PubMed ID: 30193564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.